159 related articles for article (PubMed ID: 23233093)
1. Ovarian cancer : making its own rules-again.
Kohn EC; Hurteau J
Cancer; 2013 Feb; 119(3):474-6. PubMed ID: 23233093
[TBL] [Abstract][Full Text] [Related]
2. [Molecular signatures in ovarian carcinoma].
Singer G
Praxis (Bern 1994); 2005 Oct; 94(40):1561-3. PubMed ID: 16245918
[No Abstract] [Full Text] [Related]
3. [Genetic abnormalities in the pathogenesis of ovarian cancer].
Yoshino K; Ueda Y; Kimura T; Kobayashi E; Fujita M; Enomoto T
Nihon Rinsho; 2012 Jun; 70 Suppl 4():480-7. PubMed ID: 23156294
[No Abstract] [Full Text] [Related]
4. Modelling genetic and clinical heterogeneity in epithelial ovarian cancers.
Lawrenson K; Sproul D; Grun B; Notaridou M; Benjamin E; Jacobs IJ; Dafou D; Sims AH; Gayther SA
Carcinogenesis; 2011 Oct; 32(10):1540-9. PubMed ID: 21859834
[TBL] [Abstract][Full Text] [Related]
5. Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.
Anglesio MS; Arnold JM; George J; Tinker AV; Tothill R; Waddell N; Simms L; Locandro B; Fereday S; Traficante N; Russell P; Sharma R; Birrer MJ; ; deFazio A; Chenevix-Trench G; Bowtell DD
Mol Cancer Res; 2008 Nov; 6(11):1678-90. PubMed ID: 19010816
[TBL] [Abstract][Full Text] [Related]
6. Unmasking the role of KRAS and BRAF pathways in MSI colorectal tumors.
Seruca R; Velho S; Oliveira C; Leite M; Matos P; Jordan P
Expert Rev Gastroenterol Hepatol; 2009 Feb; 3(1):5-9. PubMed ID: 19210107
[No Abstract] [Full Text] [Related]
7. [Molecular genetic of ovarian cancer].
Yanaihara N; Okamoto A; Ochiai K; Tanaka T
Nihon Rinsho; 2012 Jun; 70 Suppl 4():475-9. PubMed ID: 23156293
[No Abstract] [Full Text] [Related]
8. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
[TBL] [Abstract][Full Text] [Related]
9. P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas.
Sundov D; Caric A; Mrklic I; Gugic D; Capkun V; Hofman ID; Mise BP; Tomic S
Diagn Pathol; 2013 Feb; 8():21. PubMed ID: 23388101
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer as a genetic disease.
Lech A; Daneva T; Pashova S; Gagov H; Crayton R; Kukwa W; Czarnecka AM; Szczylik C
Front Biosci (Landmark Ed); 2013 Jan; 18(2):543-63. PubMed ID: 23276941
[TBL] [Abstract][Full Text] [Related]
11. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
[TBL] [Abstract][Full Text] [Related]
12. Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma.
Benedix F; Meyer F; Kube R; Kropf S; Kuester D; Lippert H; Roessner A; Krüger S
Pathol Res Pract; 2012 Oct; 208(10):592-7. PubMed ID: 22898351
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathogenesis of borderline and invasive ovarian tumors.
Stanojevic Z; Djordjevic B; Pajovic SB; Zivanov-Curlis J; Najman S
J BUON; 2009; 14(1):7-18. PubMed ID: 19373941
[TBL] [Abstract][Full Text] [Related]
14. KRAS signaling pathway alterations in microsatellite unstable gastrointestinal cancers.
Velho S; Corso G; Oliveíra C; Seruca R
Adv Cancer Res; 2010; 109():123-43. PubMed ID: 21070916
[TBL] [Abstract][Full Text] [Related]
15. Impact of KRAS and BRAF gene mutations on targeted therapies in colorectal cancer.
Bass A
J Clin Oncol; 2011 Jul; 29(19):2728-9. PubMed ID: 21646605
[No Abstract] [Full Text] [Related]
16. Distinct Binding Preferences between Ras and Raf Family Members and the Impact on Oncogenic Ras Signaling.
Terrell EM; Durrant DE; Ritt DA; Sealover NE; Sheffels E; Spencer-Smith R; Esposito D; Zhou Y; Hancock JF; Kortum RL; Morrison DK
Mol Cell; 2019 Dec; 76(6):872-884.e5. PubMed ID: 31606273
[TBL] [Abstract][Full Text] [Related]
17. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis.
Kurman RJ; Visvanathan K; Roden R; Wu TC; Shih IeM
Am J Obstet Gynecol; 2008 Apr; 198(4):351-6. PubMed ID: 18395030
[TBL] [Abstract][Full Text] [Related]
18. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
Kimura ET; Nikiforova MN; Zhu Z; Knauf JA; Nikiforov YE; Fagin JA
Cancer Res; 2003 Apr; 63(7):1454-7. PubMed ID: 12670889
[TBL] [Abstract][Full Text] [Related]
19. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.
George J; Alsop K; Etemadmoghadam D; Hondow H; Mikeska T; Dobrovic A; deFazio A; ; Smyth GK; Levine DA; Mitchell G; Bowtell DD
Clin Cancer Res; 2013 Jul; 19(13):3474-84. PubMed ID: 23633455
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies.
Ross JS; Ali SM; Wang K; Palmer G; Yelensky R; Lipson D; Miller VA; Zajchowski D; Shawver LK; Stephens PJ
Gynecol Oncol; 2013 Sep; 130(3):554-9. PubMed ID: 23791828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
